Immunocore Holdings 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bahija Jallal

최고 경영자

US$11.7m

총 보상

CEO 급여 비율	6.3%
CEO 임기	6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bahija Jallal 의 보수는 Immunocore Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$47m
Jun 30 2024	n/a	n/a	-US$55m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$12m	US$735k	-US$55m
Sep 30 2023	n/a	n/a	-US$69m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$700k	-US$53m
Sep 30 2022	n/a	n/a	-US$62m
Jun 30 2022	n/a	n/a	-US$112m
Mar 31 2022	n/a	n/a	-US$156m
Dec 31 2021	US$35m	US$700k	-US$180m
Sep 30 2021	n/a	n/a	-US$150m
Jun 30 2021	n/a	n/a	-US$139m
Mar 31 2021	n/a	n/a	-US$116m
Dec 31 2020	US$1m	n/a	-US$101m

보상 대 시장: Bahija 의 총 보상 ($USD 11.68M )은 German 시장( $USD 1.50M ).

보상과 수익: 회사가 수익성이 없는 동안 Bahija 의 보상이 증가했습니다.

CEO

Bahija Jallal (63 yo)

6yrs

테뉴어

US$11,678,834

보상

Dr. Bahija Jallal, Ph.D. serves as Director of Outpace Bio, Inc. from March 2023. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limite...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bahija Jallal	CEO & Executive Director	6yrs	US$11.68m	데이터 없음
Travis Coy	CFO, Executive VP & Head of Corporate Development	no data	데이터 없음	데이터 없음
Tina Leger	Chief Human Resources Officer	2.9yrs	US$1.04m	데이터 없음
David Berman	Executive Vice President of Research & Development	6yrs	US$4.40m	0% € 0
John Trainer	SVP & Chief Operating Officer	less than a year	데이터 없음	데이터 없음
John Goll	SVP, Finance & Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
Annelise Vuidepot	Senior VP	no data	데이터 없음	데이터 없음
Sean Buckley	VP & Chief Information Officer	less than a year	데이터 없음	데이터 없음
Clayton Robertson	Head of Investor Relations	no data	데이터 없음	데이터 없음
Lily Hepworth	Senior VP	4yrs	데이터 없음	데이터 없음
Elizabeth Jobes	Chief Compliance Officer	less than a year	데이터 없음	데이터 없음
Sébastien Desprez	Vice President of Communications	3yrs	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: 6YG 의 관리팀은 경험 (평균 재직 기간 2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bahija Jallal	CEO & Executive Director	6yrs	US$11.68m	데이터 없음
John Bell	Independent Non-Executive Chairman	9.8yrs	US$416.99k	0.027% € 400.4k
Kristine Peterson	Independent Non-Executive Director	7.2yrs	US$389.49k	0% € 0
Robert Perez	Independent Non-Executive Director	5.3yrs	데이터 없음	데이터 없음
Roy Steven Herbst	Independent Non-Executive Director	4yrs	US$386.99k	0% € 0
Peter Ratcliffe	Independent Non-Executive Director	4.2yrs	US$384.49k	0.00067% € 10.0k
Ranjeev Krishana	Director	less than a year	데이터 없음	데이터 없음
Siddharth Kaul	Independent Non-Executive Director	2.6yrs	US$386.99k	0% € 0

4.8yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: 6YG 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/08 08:48
장 마감 주가	2025/01/07 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Immunocore Holdings plc 22 애널리스트 중 15 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jack Allen	Baird
Peter Lawson	Barclays
Olga Smolentseva	Bryan Garnier & Co

Immunocore Holdings 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Immunocore Holdings plc Announces Cessation of Travis Coy as Director

Immunocore Holdings plc Appoints Travis Coy as Executive Vice President and Head of Corporate Development

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Recent updates

Immunocore Holdings plc Announces Cessation of Travis Coy as Director

Immunocore Holdings plc Appoints Travis Coy as Executive Vice President and Head of Corporate Development

Immunocore Holdings plc Announces First Patient Dosed in the Phase 1 Trial of IMC-P115C

Immunocore Announces Treatment of First Patient in the Phase 1/2 Trial of IMC-R117C Targeting PIWIL1 in Advanced Gastrointestinal Cancers

European Organisation for Research and Treatment of Cancer and Immunocore Holdings plc Announces Enrolment of First Patient Onto Phase 3 Adjuvant Trial in Oveal Melanoma

Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.018 in 3Q 2023)

New major risk - Revenue and earnings growth

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2023)

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 22% undervalued after recent price drop

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.09 loss in FY 2022)

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.13 in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: UK£0.29 loss per share (vs UK£0.14 loss in 2Q 2022)

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings released: UK£0.35 loss per share (vs UK£0.37 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: UK£0.90 loss per share (vs UK£3.10 loss in FY 2021)

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Third quarter 2022 earnings released: EPS: UK£0.13 (vs UK£0.69 loss in 3Q 2021)

High number of new directors

Second quarter 2022 earnings released

Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor

Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P.

Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV

High number of new directors

Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™

Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors

Immunocore Holdings plc Announces UK Medicines and Healthcare Products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada Approves Kimmtrak® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Presents New Data on KIMMTRAK (tebentafusp-tebn) in metastatic Cutaneous Melanoma (mCM) and metastatic Uveal Melanoma (mUM) at the 2022 American Society of Clinical Oncology Annual Meeting

Immunocore Announces Upcoming Presentations At the 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: UK£0.37 loss per share (vs UK£0.76 loss in 1Q 2021)

Immunocore Holdings plc, Annual General Meeting, May 12, 2022

European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Immunocore Holdings plc Receives Positive CHMP Opinion for KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Announces Approval from the United States Food and Drug Administration of KIMMTRAK for the Treatment of Unresectable or Metastatic Uveal Melanoma

Third quarter 2021 earnings released: UK£0.69 loss per share (vs UK£0.064 loss in 3Q 2020)

Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigator’s Choice in the New England Journal of Medicine

Immunocore Presents Data At the European Society for Medical Oncology (Esmo) Congress 2021 Demonstrating A Reduction in Circulating Tumor DNA (ctDNA) While on Tebentafusp Is Associated with Overall Survival in the Phase 2 Clinical Trial

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

An unknown buyer acquired stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Medigene AG (XTRA:MDG1) for $4.7 million.

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Second quarter 2021 earnings released: UK£0.75 loss per share (vs UK£0.63 loss in 2Q 2020)

CEO 보상 분석

CEO